---
title: "Prelude Therapeutics Incorporated (PRLD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRLD.US.md"
symbol: "PRLD.US"
name: "Prelude Therapeutics Incorporated"
industry: "Biotechnology"
datetime: "2026-05-20T16:39:35.458Z"
locales:
  - [en](https://longbridge.com/en/quote/PRLD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRLD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRLD.US.md)
---

# Prelude Therapeutics Incorporated (PRLD.US)

## Company Overview

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [reludetx.com](https://reludetx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 132 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 138.86% |  |
| Net Profit YoY | 39.14% |  |
| P/B Ratio | 4.47 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 269019598.96 |  |
| Revenue | 16720000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -95.25% | E |
| Profit Margin | -465.30% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 138.86% | A |
| Net Profit YoY | 39.14% | B |
| Total Assets YoY | -15.30% | E |
| Net Assets YoY | -41.67% | E |
| Cash Flow Margin | 56.24% | C |
| OCF YoY | 138.86% | A |
| Turnover | 0.13 | E |
| Gearing Ratio | 49.70% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Prelude Therapeutics Incorporated",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "138.86%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "39.14%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "269019598.96",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "16720000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-95.25%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-465.30%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "138.86%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "39.14%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.30%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-41.67%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "56.24%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "138.86%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "49.70%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.46 | 323/386 | - | - | - |
| PB | 4.47 | 311/386 | 3.04 | 1.77 | 0.53 |
| PS (TTM) | 16.09 | 185/386 | 17.18 | 12.16 | 7.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.37 |
| Highest Target | 8.00 |
| Lowest Target | 4.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PRLD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PRLD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PRLD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PRLD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**